Baxter International (NYSE:BAX) Issues Q1 2025 Earnings Guidance

Baxter International (NYSE:BAX) updated its first quarter 2025 earnings guidance on Thursday. The company provided EPS guidance of 0.470-0.500 for the period, compared to the consensus EPS estimate of 0.490. The company issued revenue guidance of $3.7 billion-$3.7 billion, compared to the consensus revenue estimate of $2.6 billion. Baxter International also updated its FY 2025 guidance to 2.450-2.550 EPS.

Baxter International Stock Performance

Shares of BAX stock opened at $30.86 on Thursday. The company has a current ratio of 1.43, a quick ratio of 1.09 and a debt-to-equity ratio of 1.31. The company has a market cap of $15.75 billion, a PE ratio of 154.28, a P/E/G ratio of 9.83 and a beta of 0.61. The company’s fifty day simple moving average is $30.52 and its 200-day simple moving average is $34.15. Baxter International has a 52 week low of $28.33 and a 52 week high of $44.01.

Baxter International (NYSE:BAX) last released its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $0.58 EPS for the quarter, beating the consensus estimate of $0.52 by $0.06. Baxter International had a return on equity of 18.30% and a net margin of 0.77%. As a group, equities research analysts anticipate that Baxter International will post 1.83 EPS for the current year.

Baxter International Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 1st. Stockholders of record on Friday, February 28th will be paid a dividend of $0.17 per share. The ex-dividend date of this dividend is Friday, February 28th. This represents a $0.68 dividend on an annualized basis and a dividend yield of 2.20%. Baxter International’s dividend payout ratio is currently 340.02%.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on BAX. StockNews.com lowered shares of Baxter International from a “buy” rating to a “hold” rating in a report on Monday, November 11th. Citigroup lowered their target price on Baxter International from $37.00 to $35.00 and set a “neutral” rating for the company in a research note on Wednesday, December 11th. Finally, Stifel Nicolaus cut their price target on Baxter International from $46.00 to $38.00 and set a “buy” rating on the stock in a research note on Monday, November 11th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $39.44.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.